Endocrinology

As physicians treat more diverse patient populations, the importance of communicating properly with patients can have resounding effects on outcomes and adherence.

Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.

Both the intention-to-treat and on-treatment principles reported significant blood sugar reductions from the oral GLP-1 analogue.

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

More people achieved weight reduction of ≥5% and ≥10% with semaglutide in all BMI subgroups.

The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.

The Healthy MOMs program resulted in positive improvements in diet and depressive symptoms for expecting Latinas, a population at a high risk for gestational and type 2 diabetes.

The authorization of these 2 devices allows for less-invasive vascular access options for patients requiring hemodialysis.

The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.

The expanded indication provides an important treatment option for clinicians and patients with type 1 diabetes.

The system’s algorithm predicts glucose levels 30 minutes in advance and adjusts insulin delivery to reduce hypoglycemic events.

NOCDURNA is the first and only sublingual tablet indicated for treatment of nocturia due to nocturnal polyuria in adults awakening at least 2 times per night to urinate.

The Eversense CGM System sensor is implanted into the patient’s arm and sends glucose data every 5 minutes to a mobile app.

The investigative GLP-1 receptor agonist was compared to liraglutide, sitagliptin, and placebo in adult patients with type 2 diabetes.

The results suggest that this approach could streamline the diagnosis of diabetes, losing the need for the same elevated test needing to be repeated in a new blood sample.

The first patient is anticipated to be enrolled in the third quarter of 2018, and topline results will be expected by the beginning of 2020.

The software is now indicated to assist physicians treating patients with T1D who use insulin pumps and continuous glucose monitoring.

Montefiore has made it a point to seek to improve the health of its patients in the classroom, the doctor’s office, and the community itself.

When your patient is also your neighbor it can get, well, awkward. That's why Melissa Young, MD, has shared her tips on how to handle seeing patients outside of the office. 

How can less exercise yield better blood sugar and decrease risk of heart disease in diabetes patients? A new study has answers. 

The most recent approval in the class, ertugliflozin (Steglatro), is a product of the efforts of a duo of pharmaceutical giants, Pfizer and Merck.

A growing class of medications, SGLT-2 inhibitors have helped physicians manage otherwise uncontrolled cases of type 2 diabetes.

According to BioMarin, the therapy is expected to be available in June 2018, with marketing beginning immediately.

The oral dual inhibitor is intended to work alongside insulin therapy to improve blood sugar control in adults with type 1 diabetes.

The therapy showed reduction in nighttime resting heart rate comparable to that of beta blockers.